{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:56:31Z","timestamp":1781643391837,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In patients with classical Hodgkin lymphoma (c-HL) undergoing ABVD chemotherapy for advanced disease, the optimal strategy to prevent febrile neutropenia (FN)\u2014defined as fever\u2009\u2265\u200938\u00a0\u00b0C with absolute neutrophil count (ANC)\u2009&lt;\u20091000\/mm\u00b3\u2014remains debated. Possible prophylaxis approaches include:\n                    <jats:italic>i<\/jats:italic>\n                    ) secondary prophylaxis with on-demand granulocyte colony-stimulating factor (G-CSF, filgrastim),\n                    <jats:italic>ii<\/jats:italic>\n                    ) primary prophylaxis with filgrastim, or\n                    <jats:italic>iii<\/jats:italic>\n                    ) primary prophylaxis with long-acting G-CSF formulations such as pegylated or glyco-pegylated G-CSF (lipegfilgrastim). We conducted a multicenter retrospective cohort study from 2010 to 2024 involving 450 untreated c-HL patients (Ann Arbor stage IIB-IV) scheduled for six ABVD cycles, divided into three five-year periods, each with a different G-CSF prophylaxis strategy. From 2010 to 2014, 131 patients received on-demand filgrastim when ANC\u2009\u2264\u20091\u2009\u00d7\u200910^9\/L (\n                    <jats:italic>on-demand<\/jats:italic>\n                    - group); from 2015 to 2019, 152 patients systematically received filgrastim six times per cycle (\n                    <jats:italic>filgrastim-<\/jats:italic>\n                    group); from 2020 to 2024, 167 patients received lipegfilgrastim twice per cycle as primary prophylaxis (\n                    <jats:italic>lipegfilgrastim<\/jats:italic>\n                    -group). A total of 85 neutropenia episodes occurred: 52 in the\n                    <jats:italic>on-demand<\/jats:italic>\n                    -group, 30 in the\n                    <jats:italic>filgrastim<\/jats:italic>\n                    -group, and 3 in the\n                    <jats:italic>lipegfilgrastim<\/jats:italic>\n                    -group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001); FN incidence was 24%, 14%, and 2%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Chemotherapy disruptions due to FN were 14%, 6%, and 1%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Grade 3 bone pain occurred in 5% of patients and was managed with analgesics. Primary prophylaxis with lipegfilgrastim significantly reduced FN rates, hospitalizations, and chemotherapy interruptions in patients with advanced-stage c-HL treated with ABVD, demonstrating improved tolerability of chemotherapy.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06911-7","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:43:27Z","timestamp":1773841407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study"],"prefix":"10.1007","volume":"105","author":[{"given":"Claudia","family":"Giordano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Trastulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Secchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Postorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"14","key":"6911_CR1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211.","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 36(14):1443\u20131453. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211.","journal-title":"J Clin Oncol"},{"issue":"6","key":"6911_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jnccn.2020.0067","volume":"18","author":"RT Hoppe","year":"2020","unstructured":"Hoppe RT, Advani RH, Ai WZ et al (2020) Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(6):755\u2013775. https:\/\/doi.org\/10.6004\/jnccn.2020.0067","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"6911_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/curroncol28020116","volume":"28","author":"J Graczyk","year":"2021","unstructured":"Graczyk J, Cheung MC, Buckstein R, Chan K (2021) Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a decision analysis. Curr Oncol 28(2):1241\u20131252. https:\/\/doi.org\/10.3390\/curroncol28020116","journal-title":"Curr Oncol"},{"issue":"5\u20136","key":"6911_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/10428199509057696","volume":"19","author":"K Clarke","year":"1995","unstructured":"Clarke K, Grigg A (1995) Intermittent G\u2013CSF to maintain dose intensity of chemotherapy for Hodgkin\u2019s disease. Leuk Lymphoma 19(5\u20136):521\u2013522. https:\/\/doi.org\/10.3109\/10428199509057696","journal-title":"Leuk Lymphoma"},{"issue":"3\u20134","key":"6911_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/10428190120042495","volume":"41","author":"A Rueda","year":"2001","unstructured":"Rueda A, Sevilla I, Gum\u00e0 J, Ribelles N, Miram\u00f3n J, De Las Nieves MA et al (2001) Secondary prophylactic G\u2013CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin\u2019s lymphoma with ABVD. Leuk Lymphoma 41(3\u20134):353\u2013358. https:\/\/doi.org\/10.1080\/10428190120042495","journal-title":"Leuk Lymphoma"},{"key":"6911_CR6","doi-asserted-by":"publisher","unstructured":"Bohlius J, Reiser M, Schwarzer G, Engert A (2004) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 1CD003189. https:\/\/doi.org\/10.1002\/14651858.CD003189.pub2","DOI":"10.1002\/14651858.CD003189.pub2"},{"key":"6911_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00520-022-07598-2","volume":"31","author":"MS Aapro","year":"2023","unstructured":"Aapro MS, Chaplin S, Cornes P et al (2023) Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Support Care Cancer 31:581. https:\/\/doi.org\/10.1007\/s00520-022-07598-2","journal-title":"Support Care Cancer"},{"issue":"11","key":"6911_CR8","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1182\/blood-2006-03-011344","volume":"108","author":"R Pettengell","year":"2006","unstructured":"Pettengell R, Bosly A, Szucs TD et al (2006) Impact of febrile neutropenia and colony stimulating factor use on chemotherapy delivery in patients with lymphoma: results from the INC-EU prospective observational European Neutropenia Study. Blood 108(11):2444. https:\/\/doi.org\/10.1182\/blood-2006-03-011344","journal-title":"Blood"},{"issue":"10","key":"6911_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.annonc.2020.06.010","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Banerjee S, Cervantes A et al (2020) Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 31(10):1320\u20131335. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.010","journal-title":"Ann Oncol"},{"key":"6911_CR10","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.2147\/IJN.S96413","volume":"10","author":"M Gasparic","year":"2015","unstructured":"Gasparic M, Leyman S (2015) Review on lipegfilgrastim. Int J Nanomedicine 10:6863\u20136874. https:\/\/doi.org\/10.2147\/IJN.S96413","journal-title":"Int J Nanomedicine"},{"key":"6911_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase III trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer 13:386. https:\/\/doi.org\/10.1186\/1471-2407-13-386","journal-title":"BMC Cancer"},{"issue":"6","key":"6911_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1078155217710820","volume":"24","author":"TC Bond","year":"2018","unstructured":"Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U et al (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24(6):412\u2013423. https:\/\/doi.org\/10.1177\/1078155217710820","journal-title":"J Oncol Pharm Pract"},{"key":"6911_CR13","doi-asserted-by":"publisher","unstructured":"Picardi M, Della Pepa R, Giordano C et al (2019) (1\u20133)-\u03b2-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations. Ann Hematol. ;98(2):527\u2013531. https:\/\/doi.org\/10.1007\/s00277-018-3441-3. PMID: 30033485","DOI":"10.1007\/s00277-018-3441-3"},{"key":"6911_CR14","doi-asserted-by":"publisher","unstructured":"Della Pepa R, Cerchione C, Pugliese N et al (2018) Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3-\u03b2-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography. Support Care Cancer. ;26(6):1691\u20131694. https:\/\/doi.org\/10.1007\/s00520-018-4138-9. PMID: 29523967","DOI":"10.1007\/s00520-018-4138-9"},{"key":"6911_CR15","doi-asserted-by":"publisher","unstructured":"Picardi M, Pagliuca S, Chiurazzi F et al (2012) Early ultrasonographic finding of septic thrombophlebitis is the main indicator of central venous catheter removal to reduce infection-related mortality in neutropenic patients with bloodstream infection. Ann Oncol. ;23(8):2122\u20132128. https:\/\/doi.org\/10.1093\/annonc\/mdr588. PMID: 22228450","DOI":"10.1093\/annonc\/mdr588"},{"key":"6911_CR16","unstructured":"U.S. Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published November 27"},{"issue":"12","key":"6911_CR17","doi-asserted-by":"publisher","first-page":"9877","DOI":"10.1007\/s00520-022-07456-3","volume":"30","author":"V Adamo","year":"2022","unstructured":"Adamo V, Antonuzzo L, Danova M et al (2022) Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement. Support Care Cancer 30(12):9877\u20139888. https:\/\/doi.org\/10.1007\/s00520-022-07456-3","journal-title":"Support Care Cancer"},{"key":"6911_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.7175\/fe.v12i3.126","volume":"12","author":"G Rosti","year":"2011","unstructured":"Rosti G et al (2011) Analisi di budget impact sull\u2019utilizzo di pegfilgrastim nella profilassi della neutropenia febbrile in Italia. Farmeconomia Health Econ Ther Pathways 12:119\u2013127","journal-title":"Farmeconomia Health Econ Ther Pathways"},{"issue":"1","key":"6911_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7175\/fe.v23i1.1516","volume":"23","author":"P Berto","year":"2022","unstructured":"Berto P, Bellone M, Sabinot A, Pinto C, Martino M, Generali D, Carriero PL, Sanna MD (2022) Budget saving potential of pegfilgrastim biosimilar for the treatment of chemotherapy induced febrile neutropenia in Italy. Farmeconomia Health Econ Ther Pathways 23(1):1\u201312. https:\/\/doi.org\/10.7175\/fe.v23i1.1516","journal-title":"Farmeconomia Health Econ Ther Pathways"},{"issue":"10","key":"6911_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S et al (2020) Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 135(10):735\u2013742. https:\/\/doi.org\/10.1182\/blood.2019003127","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06911-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:25:20Z","timestamp":1781641520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06911-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6911"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06911-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7924231\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All necessary approvals were obtained from the Ethic Committee of the coordinator center Federico II University of Naples (approval protocol number: 66\/2024). The study was undertaken in accordance with the Declaration of Helsinki. The acquisition of a written informed consent was obtained from each patient undergoing chemotherapy treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}